These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1181 related items for PubMed ID: 25713985

  • 21. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H, Lietzan E, Faccin F, Venema J.
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K, Molnár T.
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [First biosimilar infliximab approved].
    Neumaier J.
    MMW Fortschr Med; 2015 Mar 26; 157 Suppl 1():88. PubMed ID: 26013000
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, Kim SH, Jung NH, Park JE, Lee YJ, Jeon DB, Lee YM, Kim JM, Park SH.
    Adv Ther; 2021 Aug 26; 38(8):4366-4387. PubMed ID: 34250583
    [Abstract] [Full Text] [Related]

  • 31. Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description.
    Meacci F, Manfredi M, Infantino M, Grossi V, Benucci M.
    Ann Rheum Dis; 2016 Oct 26; 75(10):e62. PubMed ID: 27401744
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S, Panés J, Kwon B, Hong S, Peyrin-Biroulet L.
    Expert Rev Gastroenterol Hepatol; 2015 Oct 26; 9 Suppl 1():5-15. PubMed ID: 26395530
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA.
    Eur J Clin Pharmacol; 2018 May 26; 74(5):655-661. PubMed ID: 29368188
    [Abstract] [Full Text] [Related]

  • 38. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ, Klein AV, Wang J.
    J Clin Pharmacol; 2015 Mar 26; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [Abstract] [Full Text] [Related]

  • 39. Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
    Magro F, Coelho R, Peixoto A.
    Curr Med Chem; 2019 Mar 26; 26(2):248-258. PubMed ID: 30381062
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.